Inventor · disambiguated record
Michel Rivier
Also filed as: RIVIER MICHEL
16 granted patents·18 pending applications·69 citations·filing 1998–2016
89Inventor score
Top patents by PatentIndex Score
34 records- 0182US7625914B2Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2005·Granted Dec 1, 2009·5 cites·38 claims
- 0280US7125869B2Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2005·Granted Oct 24, 2006·4 cites·81 claims
- 0379US6403656B1Use of ppar-γ activators in dermatologyGALDERMA RES & DEV·Filed 1998·Granted Jun 11, 2002·51 cites·9 claims
- 0478US7307078B2Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2006·Granted Dec 11, 2007·3 cites·81 claims
- 0578US7285568B2Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2005·Granted Oct 23, 2007·4 cites·14 claims
- 0675US7452878B2Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2005·Granted Nov 18, 2008·2 cites·15 claims
- 0765US8022079B2Methods of modulating PPAR gamma-type receptorsGALDERMA RES & DEV·Filed 2009·Granted Sep 20, 2011·0 cites·34 claims
- 0865US7968560B2Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compoundsGALDERMA RES & DEV·Filed 2009·Granted Jun 28, 2011·0 cites·31 claims
- 0961US9889126B2Use of naratriptan in the treatment of rosaceaGALDERMA RES & DEV·Filed 2014·Granted Feb 13, 2018·0 cites·16 claims
- 1061US7973063B2Methods for activating PPAR gamma-type receptorsGALDERMA RES & DEV·Filed 2009·Granted Jul 5, 2011·0 cites·37 claims
- 1159US7807669B2Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2008·Granted Oct 5, 2010·0 cites·16 claims
- 1259US2011150774A1Screening for modulators of ces1 and/or ces3 for the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 1358US2011262450A1Modulators of monoglyceride lipase in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaREINICHE PASCALE·Filed 2009·Application pending·0 cites
- 1456US7626054B2Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2006·Granted Dec 1, 2009·0 cites·56 claims
- 1554US2011268742A1Pctp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 1654US2007065471A1Cosmetic/dermatological applications of PPAR receptor activatorsGALDERMA RES & DEV·Filed 2006·Application pending·0 cites
- 1751US10048279B2Method for the diagnosis of rosaceaGALDERMA RES & DEV·Filed 2012·Granted Aug 14, 2018·0 cites·12 claims
- 1850US8383652B2Biaromatic compounds that modulate PPAR-receptorsGALDERMA RES & DEV·Filed 2008·Granted Feb 26, 2013·0 cites·34 claims
- 1950US2011165168A1Cidea modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2050US2011150772A1Modulators of carnitine octanoyltransferase in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2150US2011150773A1Modulators of acetyl-coenzyme a acyltransferase 1 or 2 in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2249US2011262451A1Modulators of isovaleryl-coenzyme a dehydrogenase in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaAUBERT JEROME·Filed 2009·Application pending·0 cites
- 2348US2011229423A1Pacap signaling pathway modulators for treating inflammatory skin diseases having a neurogenic component, notably rosacea, and compositions comprised thereofGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2448US2010028878A1Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinizationGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2547US7582663B2Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereofGALDERMA RES & DEV·Filed 2007·Granted Sep 1, 2009·0 cites·18 claims
- 2647US2011189686A1Screening for modulators of cyp2b15 and/or gpd1 for the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoeaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2747US2010028879A1Modulators of HSD17b7 for treating acne or hyperseborrheaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 2846US9408793B2Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositionsGALDERMA RES & DEV·Filed 2013·Granted Aug 9, 2016·0 cites·18 claims
- 2946US2009298074A1Modulators of ELOVL5 for treating acne or hyperseborrheaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 3046US2009258356A1Modulators of the transporter ABCD3 for treating acne or hyperseborrheaGALDERMA RES & DEV·Filed 2009·Application pending·0 cites
- 3139US2013017969A1Markers and method for the diagnosis of rosaceaUNI MUNSTER·Filed 2010·Application pending·0 cites
- 3234US2018185360A1Cgrp receptor antagonist compounds for topical treatment of skin disordersGALDERMA RES & DEV·Filed 2016·Application pending·0 cites
- 3330US2017020833A1Method for treating and/or preventing acne scars with a fixed combination of adapalene or its salts and benzoyl peroxideGALDERMA RES & DEV·Filed 2015·Application pending·0 cites
- 3422US2010168231A1Target enzyme for the treatment of acneGALDERMA RES & DEV·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michel Rivier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →